<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>AMOXICILLIN
                                    Â - amoxicillinÂ capsuleÂ </strong><br>TYA Pharmaceuticals<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">These highlights do not include all the information needed to use amoxicillin capsulesÂ safely and effectively. See full prescribing information for amoxicillin capsules, USP. Amoxicillin Capsules, USP Initial U.S. Approval: 1974 To reduce the development of drug-resistant bacteria and maintain the effectiveness of amoxicillin capsules, USP and other antibacterial drugs, amoxicillin capsules, USP should be used only to treat <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> that are proven or strongly suspected to be caused by bacteria.
        <br><br><br><br><br>
</div>
<div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div>
<br><p class="Highlighta">Amoxicillin capsules, USP are a penicillin-class antibacterial indicated for treatment of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> due to susceptible <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of designated microorganisms. </p>
<br><ul class="Disc">
<li><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span> of the ear, nose, throat, genitourinary tract, skin and skin structure, and lower respiratory tract. Â -
                                        <a href="#Section_1.1">(1.1</a><a href="#Section_1.5">1.5)</a>
</li>
<li>In combination for treatment of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> and <span class="product-label-link" type="condition" conceptid="4057053" conceptname="Acute duodenal ulcer">duodenal ulcer</span> disease. ,
                                        <span class="Italics">H. pyloriÂ </span><a href="#Section_1.6">(1.6</a><a href="#Section_1.7">1.7)</a>
</li>
</ul>
</div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div><ul class="Disc">
<li>In adults, 750 to 1750 mg/day in divided doses every 8 to 12 hours. In Pediatric Patients &gt; 3 Months of Age, 20 to 45 mg/kg/day in divided doses every 8 to 12 hours. Refer to full prescribing information for specific dosing regimens. , ,
                                        <a href="#Section_2.1">(2.1</a><a href="#Section_2.2">2.2</a><a href="#Section_2.3">2.3)</a>
</li>
<li>Treatment of <span class="product-label-link" type="condition" conceptid="433417" conceptname="Gonorrhea">gonorrhea</span> is 3 grams as a single oral dose.
                                        <a href="#Section_2.1">(2.1)</a>
</li>
<li>The upper dose for neonates and infants â‰¤ 3 months is 30 mg/kg/day divided every 12 hours.
                                        <a href="#Section_2.2">(2.2)</a>
</li>
<li>Dosing for <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infection</span>: Triple Therapy: 1 gram amoxicillin, 500 mg clarithromycin, and 30 mg lansoprazole, all given twice daily (every 12 hours) for 14 days. Dual Therapy: 1 gram amoxicillin and 30 mg lansoprazole, each given three times daily (every 8 hours) for 14 days.
                                        <span class="Italics">H. pylori</span><a href="#Section_2.3">(2.3)</a>
</li>
<li>Reduce the dose in patients with severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (GFR &lt;30 mL/min).
                                        <a href="#Section_2.4">(2.4)</a>
</li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><ul class="Disc"><li>Capsules: 250 mg andÂ 500 mg
                                        <a href="#Section_3">(3)</a>
</li></ul></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><ul class="Disc"><li>History of a serious <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reaction</span> (e.g., <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span> or <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson syndrome</span>) to amoxicillin capsules or to other beta-lactams (e.g., penicillins or cephalosporins).
                                        <a href="#Section_4">(4)</a>
</li></ul></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><ul class="Disc">
<li><span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">Anaphylactic Reactions</span>: Serious and occasionally fatal <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylactic reactions</span> have been reported in patients on penicillin therapy. Serious <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylactic reactions</span> require immediate emergency treatment with supportive measures.
                                        <a href="#Section_5.1">(5.1)</a>
</li>
<li>Associated <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span> (ranging from mild <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> to fatal <span class="product-label-link" type="condition" conceptid="4272488" conceptname="Colitis">colitis</span>): Evaluate if <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> occurs.
                                        <span class="Italics">Clostridium difficile</span><a href="#Section_5.2">(5.2)</a>
</li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<br><p class="Highlighta">The most common adverse reactions (&gt; 1%) observed in clinical trials of amoxicillinÂ capsules, tablets or oral suspension were <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, and <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>.
                                    <a href="#Section_6.1">(6.1)</a><br><br><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact Aurobindo Pharma USA, Inc. at 1-866-850-2876 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.</span> </p>
</div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DRUG INTERACTIONS</span></h1>
<div><ul class="Disc">
<li>Probenicid decreases renal tubular secretion of amoxicillin which may result in increased blood levels of amoxicillin.
                                        <a href="#Section_7.1">(7.1)</a>
</li>
<li>Concomitant use of amoxicillin and oral anticoagulants may increase the prolongation of <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> time.
                                        <a href="#Section_7.2">(7.2)</a>
</li>
<li>Coadministration with allopurinol increases the risk of <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>.
                                        <a href="#Section_7.3">(7.3)</a>
</li>
<li>Amoxicillin may reduce the efficacy of oral contraceptives.
                                        <a href="#Section_7.4">(7.4)</a>
</li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>USE IN SPECIFIC POPULATIONS</span></h1>
<div><ul class="Disc"><li>Pediatric: Modify dose in patients 12 weeks or younger (â‰¤ 3 months).
                                        <a href="#Section_8.4">(8.4)</a>
</li></ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div><div></div></div>
<div><div></div></div>
<div></div>
<div></div>
<div><div></div></div>
<div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION and FDA-approved patient labeling.</p>
<p class="HighlightsRevision">Revised: 9/2014</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc">1 INDICATIONS AND USAGE</a></h1>
<h2><a href="#section-1.1" class="toc">1.1 <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span> of the Ear, Nose, and Throat</a></h2>
<h2><a href="#section-1.2" class="toc">1.2 <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span> of the Genitourinary Tract</a></h2>
<h2><a href="#section-1.3" class="toc">1.3 <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span> of the Skin and Skin Structure</a></h2>
<h2><a href="#section-1.4" class="toc">1.4 <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span> of the Lower Respiratory Tract</a></h2>
<h2><a href="#section-1.5" class="toc">1.5 <span class="product-label-link" type="condition" conceptid="433417" conceptname="Gonorrhea">Gonorrhea</span>, Acute Uncomplicated (ano-genital and urethral <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>)</a></h2>
<h2><a href="#section-1.6" class="toc">1.6 Triple Therapy for Helicobacter pylori with Clarithromycin and Lansoprazole</a></h2>
<h2><a href="#section-1.7" class="toc">1.7 Dual Therapy for H. pylori with Lansoprazole</a></h2>
<h1><a href="#section-2" class="toc">2 DOSAGE AND ADMINISTRATION</a></h1>
<h2><a href="#section-2.1" class="toc">2.1 Dosing for Adult and Pediatric Patients &gt; 3 Months of Age</a></h2>
<h2><a href="#section-2.2" class="toc">2.2 Dosing in Neonates and Infants Aged â‰¤ 12 Weeks ( â‰¤ 3 Months)</a></h2>
<h2><a href="#section-2.3" class="toc">2.3 Dosing for H. pylori <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infection</span></a></h2>
<h2><a href="#section-2.4" class="toc">2.4 Dosing in <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></a></h2>
<h1><a href="#section-3" class="toc">3 DOSAGE FORMS AND STRENGTHS</a></h1>
<h1><a href="#section-4" class="toc">4 CONTRAINDICATIONS</a></h1>
<h1><a href="#section-5" class="toc">5 WARNINGS AND PRECAUTIONS</a></h1>
<h2><a href="#section-5.1" class="toc">5.1 <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">Anaphylactic Reactions</span></a></h2>
<h2><a href="#section-5.2" class="toc">5.2 Clostridium difficile Associated <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></a></h2>
<h2><a href="#section-5.3" class="toc">5.3 Potential for Microbial Overgrowth or <span class="product-label-link" type="condition" conceptid="4207042" conceptname="Viral resistance">Bacterial Resistance</span></a></h2>
<h2><a href="#section-5.4" class="toc">5.4 Use in Patients With Mononucleosis</a></h2>
<h1><a href="#section-6" class="toc">6 ADVERSE REACTIONS</a></h1>
<h2><a href="#section-6.1" class="toc">6.1 Clinical Trials Experience</a></h2>
<h2><a href="#section-6.2" class="toc">6.2 Postmarketing or Other Experience</a></h2>
<h1><a href="#section-7" class="toc">7 DRUG INTERACTIONS</a></h1>
<h2><a href="#section-7.1" class="toc">7.1 Probenecid</a></h2>
<h2><a href="#section-7.2" class="toc">7.2 Oral Anticoagulants</a></h2>
<h2><a href="#section-7.3" class="toc">7.3 Allopurinol</a></h2>
<h2><a href="#section-7.4" class="toc">7.4 Oral Contraceptives</a></h2>
<h2><a href="#section-7.5" class="toc">7.5 Other Antibacterials</a></h2>
<h2><a href="#section-7.6" class="toc">7.6 Drug/Laboratory Interactions</a></h2>
<h1><a href="#section-8" class="toc">8 USE IN SPECIFIC POPULATIONS</a></h1>
<h2><a href="#section-8.1" class="toc">8.1 Pregnancy</a></h2>
<h2><a href="#section-8.2" class="toc">8.2 Labor and Delivery</a></h2>
<h2><a href="#section-8.3" class="toc">8.3 Nursing Mothers</a></h2>
<h2><a href="#section-8.4" class="toc">8.4 Pediatric Use</a></h2>
<h2><a href="#section-8.5" class="toc">8.5 Geriatric Use</a></h2>
<h2><a href="#section-8.6" class="toc">8.6 Dosing in <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></a></h2>
<h1><a href="#section-9" class="toc">10 OVERDOSAGE</a></h1>
<h1><a href="#section-10" class="toc">11 DESCRIPTION</a></h1>
<h1><a href="#section-11" class="toc">12 CLINICAL PHARMACOLOGY</a></h1>
<h2><a href="#section-11.1" class="toc">12.1 Mechanism of Action</a></h2>
<h2><a href="#section-11.2" class="toc">12.3 Pharmacokinetics</a></h2>
<h2><a href="#section-11.3" class="toc">12.4 Microbiology</a></h2>
<h1><a href="#section-12" class="toc">13 NONCLINICAL TOXICOLOGY</a></h1>
<h2><a href="#section-12.1" class="toc">13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</a></h2>
<h1><a href="#section-13" class="toc">14 CLINICAL STUDIES</a></h1>
<h2><a href="#section-13.1" class="toc">14.1 H. pylori Eradication to Reduce the Risk of <span class="product-label-link" type="condition" conceptid="4057053" conceptname="Acute duodenal ulcer">Duodenal Ulcer</span> Recurrence</a></h2>
<h1><a href="#section-14" class="toc">15 REFERENCES</a></h1>
<h1><a href="#section-15" class="toc">16 HOW SUPPLIED/STORAGE AND HANDLING</a></h1>
<h1><a href="#section-16" class="toc">17 PATIENT COUNSELING INFORMATION</a></h1>
<h2><a href="#section-16.1" class="toc">17.1 Information for Patients</a></h2>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="Section_1"></a><a name="section-1"></a><p></p>
<h1>1 INDICATIONS AND USAGE</h1>
<br><p class="First">To reduce the development of drug-resistant bacteria and maintain the effectiveness of amoxicillin capsules, USPÂ and other antibacterial drugs, amoxicillin capsules, USP should be used only to treat <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> that are proven or strongly suspected to be caused by bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.Â  Amoxicillin capsules, USP are indicated in the treatment of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> due to susceptible (ONLY Î²-lactamaseâ€“negative) isolates of the designated bacteria in the conditions listed below:
                            <br><br></p>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_1.1"></a><a name="section-1.1"></a><p></p>
<h2>1.1 <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span> of the Ear, Nose, and Throat</h2>
<br><p class="First">Due to species (Î±- and Î²-hemolytic isolates only), , spp., or .
                                    <span class="Italics">Streptococcus</span><span class="Italics">Streptococcus pneumoniae</span><span class="Italics">Staphylococcus</span><span class="Italics">Haemophilus influenzae</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_1.2"></a><a name="section-1.2"></a><p></p>
<h2>1.2 <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span> of the Genitourinary Tract</h2>
<br><p class="First">Due to , or .
                                    <span class="Italics">Escherichia coli, Proteus mirabilis</span><span class="Italics">Enterococcus faecalis</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_1.3"></a><a name="section-1.3"></a><p></p>
<h2>1.3 <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span> of the Skin and Skin Structure</h2>
<br><p class="First">Due to spp. (Î±- and Î²-hemolytic isolates only), spp., or .
                                    <span class="Italics">Streptococcus</span><span class="Italics">Staphylococcus</span><span class="Italics">E. coli</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_1.4"></a><a name="section-1.4"></a><p></p>
<h2>1.4 <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span> of the Lower Respiratory Tract</h2>
<br><p class="First">Due to spp. (Î±- and Î²-hemolytic isolates only), spp., or .
                                    <span class="Italics">Streptococcus</span><span class="Italics">S. pneumoniae, Staphylococcus</span><span class="Italics">H. influenzae</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_1.5"></a><a name="section-1.5"></a><p></p>
<h2>1.5 <span class="product-label-link" type="condition" conceptid="433417" conceptname="Gonorrhea">Gonorrhea</span>, Acute Uncomplicated (ano-genital and urethral <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>)</h2>
<br><p class="First">Due to .Â  Because of high rates of amoxicillin resistance, amoxicillin capsules, USPÂ are not recommended for empiric treatment of <span class="product-label-link" type="condition" conceptid="433417" conceptname="Gonorrhea">gonorrhea</span>. Amoxicillin capsules, USP use should be limited to situations where isolates are known to be susceptible to amoxicillin.
                                    <span class="Italics">Neisseria gonorrhoeae</span><br><br><span class="Italics">N. gonorrhoeae</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_1.6"></a><a name="section-1.6"></a><p></p>
<h2>1.6 Triple Therapy for Helicobacter pylori with Clarithromycin and Lansoprazole</h2>
<br><p class="First">Amoxicillin capsules, USP, in combination with clarithromycin plus lansoprazole as triple therapy,Â are indicated for the treatment of patients with <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> and <span class="product-label-link" type="condition" conceptid="4057053" conceptname="Acute duodenal ulcer">duodenal ulcer</span> disease (active or 1-year history of a <span class="product-label-link" type="condition" conceptid="4057053" conceptname="Acute duodenal ulcer">duodenal ulcer</span>) to eradicate . Eradication of has been shown to reduce the risk of <span class="product-label-link" type="condition" conceptid="4057053" conceptname="Acute duodenal ulcer">duodenal ulcer</span> recurrence.
                                    <span class="Italics">H. pylori</span><span class="Italics">H. pylori</span><span class="Italics">H. pylori</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_1.7"></a><a name="section-1.7"></a><p></p>
<h2>1.7 Dual Therapy for H. pylori with Lansoprazole</h2>
<br><p class="First">Amoxicillin capsules, USP, in combination with lansoprazole delayed-release capsules as dual therapy,Â are indicated for the treatment of patients with <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> and <span class="product-label-link" type="condition" conceptid="4057053" conceptname="Acute duodenal ulcer">duodenal ulcer</span> disease (active or 1-year history of a <span class="product-label-link" type="condition" conceptid="4057053" conceptname="Acute duodenal ulcer">duodenal ulcer</span>) . (See the clarithromycin package insert, MICROBIOLOGY.) Eradication of has been shown to reduce the risk of <span class="product-label-link" type="condition" conceptid="4057053" conceptname="Acute duodenal ulcer">duodenal ulcer</span> recurrence.
                                    <span class="Italics">H. pylori</span><span class="Bold">who are either allergic or intolerant to clarithromycin or in whom resistance to clarithromycin is known or suspected</span><span class="Italics">H. pylori</span></p>
</div>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="Section_2"></a><a name="section-2"></a><p></p>
<h1>2 DOSAGE AND ADMINISTRATION</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_2.1"></a><a name="section-2.1"></a><p></p>
<h2>2.1 Dosing for Adult and Pediatric Patients &gt; 3 Months of Age</h2>
<br><p class="First">Except for <span class="product-label-link" type="condition" conceptid="433417" conceptname="Gonorrhea">gonorrhea</span>, treatment should be continued for a minimum of 48 to 72 hours beyond the time that the patient becomes asymptomatic or evidence of bacterial eradication has been obtained. It is recommended that there be at least 10 daysâ€™ treatment for any <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> caused by to prevent the occurrence of acute <span class="product-label-link" type="condition" conceptid="442313" conceptname="Rheumatic fever">rheumatic fever</span>. In some <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>, therapy may be required for several weeks. It may be necessary to continue clinical and/or bacteriological follow-up for several months after cessation of therapy.Â Â 
                                    <span class="Italics">Streptococcus pyogenes</span></p>
<br><table border="0" cellpadding="0" cellspacing="0" width="644">
<caption><span>Table 1. Dosing Recommendations for Adult and Pediatric Patients &gt; 3 Months of Age</span></caption>
<thead><tr class="First Last">
<th class="Lrule Rrule Toprule" align="center"><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infection</span></th>
<th class="Lrule Rrule Toprule" align="center">Severity
                                                <span class="Sup">a</span>
</th>
<th class="Lrule Rrule Toprule" align="center">Usual Adult Dose</th>
<th class="Lrule Rrule Toprule" align="center">Usual Dose for Children &gt; 3 Months
                                                <br><span class="Sup">b</span>
</th>
</tr></thead>
<tfoot><tr class="First Last"><td colspan="4">Dosing for <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> caused by bacteria that are intermediate in their susceptibility to amoxicillin should follow the recommendations for severe <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>. The childrenâ€™s dosage is intended for individuals whose weight is less than 40 kg. Children weighing 40 kg or more should be dosed according to the adult recommendations.
                                                <span class="Sup">a</span><br><span class="Sup">b</span><br>
</td></tr></tfoot>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" rowspan="2" valign="top">Â Ear/Nose/Throat Â Skin/Skin Structure Â Genitourinary Tract
                                                <br><br><br>
</td>
<td class="Rrule" valign="top">Â Mild/Moderate
                                                <br>
</td>
<td class="Rrule" valign="top">Â 500 mg every 12 hours or Â 250 mg every 8 hours
                                                <br><br>
</td>
<td class="Rrule" valign="top">Â 25 mg/kg/day in divided doses every 12 hours Â 20 mg/kg/day in divided doses every 8 hours
                                                <br><span class="Bold">Â or</span><br><br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">Â Severe
                                                <br>
</td>
<td class="Rrule" valign="top">Â 875 mg every 12 hours or Â 500 mg every 8 hours
                                                <br><br>
</td>
<td class="Rrule" valign="top">Â 45 mg/kg/day in divided doses every 12 hours Â 40 mg/kg/day in divided doses every 8 hours
                                                <br><span class="Bold">Â or</span><br><br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">Â Lower Respiratory Â Tract
                                                <br><br>
</td>
<td class="Rrule" valign="top">Â Mild/Moderate or Severe
                                                <br>
</td>
<td class="Rrule" valign="top">Â 875 mg every 12 hours or Â 500 mg every 8 hours
                                                <br><br>
</td>
<td class="Rrule" valign="top">Â 45 mg/kg/day in divided doses every 12 hours Â 40 mg/kg/day in divided doses every 8 hours
                                                <br><span class="Bold">Â or</span><br><br>
</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" valign="top">Â <span class="product-label-link" type="condition" conceptid="433417" conceptname="Gonorrhea">Gonorrhea</span> Acute, Â uncomplicated ano Â -genital and urethral Â <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> in males Â and females
                                                <br><br><br><br><br>
</td>
<td class="Rrule" valign="top">Â 
                                                <br>
</td>
<td class="Rrule" valign="top">Â 3 grams as single oral dose
                                                <br>
</td>
<td class="Rrule" valign="top">Â  children: 50 mg/kg amoxicillin, combined with 25 mg/kg probenecid as a single dose.
                                                <span class="Underline">Prepubertal</span><br><span class="Bold">Â Note: Since probenecid is contraindicated in children under 2 years, do not use this regimen in children under 2 years of age.</span><br>
</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_2.2"></a><a name="section-2.2"></a><p></p>
<h2>2.2 Dosing in Neonates and Infants Aged â‰¤ 12 Weeks ( â‰¤ 3 Months)</h2>
<br><p class="First">Treatment should be continued for a minimum of 48 to 72 hours beyond the time that the patient becomes asymptomatic or evidence of bacterial eradication has been obtained. It is recommended that there be at least 10 daysâ€™ treatment for any <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> caused by to prevent the occurrence of acute <span class="product-label-link" type="condition" conceptid="442313" conceptname="Rheumatic fever">rheumatic fever</span>. Due to incompletely developed renal function affecting elimination of amoxicillin in this age group, the recommended upper dose of amoxicillin capsulesÂ is 30 mg/kg/day divided every 12 hours. There are currently no dosing recommendations for pediatric patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span>.
                                    <span class="Italics">Streptococcus pyogenes</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_2.3"></a><a name="section-2.3"></a><p></p>
<h2>2.3 Dosing for H. pylori <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infection</span></h2>
<br><p class="First">The recommended adult oral dose is 1 gram amoxicillin, 500 mg clarithromycin, and 30 mg lansoprazole, all given twice daily (every 12 hours) for 14 days.Â  The recommended adult oral dose is 1 gram amoxicillin and 30 mg lansoprazole, each given three times daily (every 8 hours) for 14 days.Â  Please refer to clarithromycin and lansoprazole full prescribing information.
                                    <span class="Bold">Triple Therapy:</span><br><br><span class="Bold">Dual Therapy:</span><br><br></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_2.4"></a><a name="section-2.4"></a><p></p>
<h2>2.4 Dosing in <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></h2>
<ul class="Disc">
<li>Patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span> do not generally require a reduction in dose unless the impairment is severe.</li>
<li>Severely impaired patients with a glomerular filtration rate of &lt; 30 mL/min should not receive a 875 mg dose.</li>
<li>Patients with a glomerular filtration rate of 10 to 30 mL/min should receive 500 mg or 250 mg every 12 hours, depending on the severity of the <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>.</li>
<li>Patients with a glomerular filtration rate less than 10 mL/min should receive 500 mg or 250 mg every 24 hours, depending on severity of the <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>.</li>
<li>Hemodialysis patients should receive 500 mg or 250 mg every 24 hours, depending on severity of the <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>. They should receive an additional dose both during and at the end of dialysis.</li>
</ul>
</div>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="Section_3"></a><a name="section-3"></a><p></p>
<h1>3 DOSAGE FORMS AND STRENGTHS</h1>
<br><p class="First">are blue/pink size â€œ1â€? hard gelatin capsule filled with white to off white granular powder and imprinted with â€œA44â€? on pink body with black ink. are blue/pink size â€œ0ELâ€? hard gelatin capsule filled with white to off white granular powder and imprinted with â€œA45â€? on pink body with black ink.
                            <span class="Bold">250 mg Capsule</span><br><br><span class="Bold">500 mg Capsule</span></p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="Section_4"></a><a name="section-4"></a><p></p>
<h1>4 CONTRAINDICATIONS</h1>
<br><p class="First">Amoxicillin capsules areÂ  contraindicated in patients who have experienced a serious <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reaction</span> (e.g., <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span> or <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson syndrome</span>) to amoxicillin capsules or to other Î²-lactam antibiotics (e.g., penicillins and cephalosporins).</p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="Section_5"></a><a name="section-5"></a><p></p>
<h1>5 WARNINGS AND PRECAUTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_5.1"></a><a name="section-5.1"></a><p></p>
<h2>5.1 <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">Anaphylactic Reactions</span></h2>
<br><p class="First">Serious and occasionally fatal <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> (anaphylactic) reactions have been reported in patients on penicillin therapy including amoxicillin. Although <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span> is more frequent following parenteral therapy, it has occurred in patients on oral penicillins. These reactions are more likely to occur in individuals with a history of penicillin <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> and/or a history of sensitivity to multiple allergens. There have been reports of individuals with a history of penicillin <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> who have experienced severe reactions when treated with cephalosporins. Before initiating therapy with amoxicillin, careful inquiry should be made regarding previous <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span> to penicillins, cephalosporins, or other allergens.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_5.2"></a><a name="section-5.2"></a><p></p>
<h2>5.2 Clostridium difficile Associated <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></h2>
<br><p class="First">associated <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> (CDAD) has been reported with use of nearly all antibacterial agents, including amoxicillin, and may range in severity from mild <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> to fatal <span class="product-label-link" type="condition" conceptid="4272488" conceptname="Colitis">colitis</span>. Treatment with antibacterial agents alters the normal flora of the colon leading to overgrowth of produces toxins A and B which contribute to the development of CDAD. Hypertoxin-producing <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of cause increased morbidity and mortality, as these <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> can be refractory to antimicrobial therapy and may require colectomy. CDAD must be considered in all patients who present with <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> following antibacterial use. Careful medical history is necessary since CDAD has been reported to occur over 2 months after the administration of antibacterial agents. If CDAD is suspected or confirmed, ongoing antibiotic use not directed against may need to be discontinued. Appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of , and surgical evaluation should be instituted as clinically indicated.
                                    <span class="Italics">Clostridium difficile</span><span class="Italics">C. difficile. C. difficile
                                        <br><br></span><span class="Italics">C. difficile</span><br><br><span class="Italics">C. difficile</span><span class="Italics">C. difficile</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_5.3"></a><a name="section-5.3"></a><p></p>
<h2>5.3 Potential for Microbial Overgrowth or <span class="product-label-link" type="condition" conceptid="4207042" conceptname="Viral resistance">Bacterial Resistance</span></h2>
<br><p class="First">The possibility of <span class="product-label-link" type="condition" conceptid="4105019" conceptname="Superimposed infection">superinfections</span> with fungal or bacterial pathogens should be considered during therapy. If <span class="product-label-link" type="condition" conceptid="4105019" conceptname="Superimposed infection">superinfections</span> occur, amoxicillin should be discontinued and appropriate therapy instituted. Prescribing amoxicillin either in the absence of a proven or strongly suspected <span class="product-label-link" type="condition" conceptid="432545" conceptname="Bacterial infectious disease">bacterial infection</span> is unlikely to provide benefit to the patient, and increases the risk of the development of drug-resistant bacteria.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_5.4"></a><a name="section-5.4"></a><p></p>
<h2>5.4 Use in Patients With Mononucleosis</h2>
<br><p class="First">A high percentage of patients with mononucleosis who receive amoxicillin develop an erythematous <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">skin rash</span>. Thus amoxicillin should not be administered to patients with mononucleosis.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="Section_6"></a><a name="section-6"></a><p></p>
<h1>6 ADVERSE REACTIONS</h1>
<br><p class="First">The following are discussed in more detail in other sections of the labeling:</p>
<br><br><ul class="Disc">
<li><span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">Anaphylactic reactions</span>
                                <span class="Italics">[see ]
                                    <a href="#Section_5.1">Warnings and Precautions (5.1)</a></span>
</li>
<li>CDAD
                                <span class="Italics">[see ]
                                    <a href="#Section_5.2">Warnings and Precautions (5.2)</a></span>
</li>
</ul>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_6.1"></a><a name="section-6.1"></a><p></p>
<h2>6.1 Clinical Trials Experience</h2>
<br><p class="First">Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.Â  The most common adverse reactions (&gt; 1%) observed in clinical trials of amoxicillin capsules, tablets or oral suspensionÂ were <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, and <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>.Â 
                                    <br><br><br><br><span class="Bold">Triple Therapy:</span></p>
<span class="Italics"></span><p>The most frequently reported adverse events for patients who received triple therapy (amoxicillin/clarithromycin/lansoprazole) were <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> (7%), <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> (6%), and <span class="product-label-link" type="condition" conceptid="436235" conceptname="Taste sense altered">taste perversion</span> (5%).Â 
                                    <br><br><span class="Bold">Dual Therapy:</span></p>
<span class="Italics"></span><p>The most frequently reported adverse events for patients who received double therapy amoxicillin/lansoprazole were <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> (8%) and <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> (7%). For more information on adverse reactions with clarithromycin or lansoprazole, refer to the Adverse Reactions section of their package inserts.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_6.2"></a><a name="section-6.2"></a><p></p>
<h2>6.2 Postmarketing or Other Experience</h2>
<br><p class="First">In addition to adverse events reported from clinical trials, the following events have been identified during postmarketing use of penicillins. Because they are reported voluntarily from a population of unknown size, estimates of frequency cannot be made. These events have been chosen for inclusion due to a combination of their seriousness, frequency of reporting, or potential causal connection to amoxicillin.</p>
<br><br><ul class="Disc">
<li><span class="product-label-link" type="condition" conceptid="4104522" conceptname="Mucocutaneous candidiasis">Mucocutaneous candidiasis</span>.
                                        <span class="Bold"><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span> and <span class="product-label-link" type="condition" conceptid="432251" conceptname="Disease caused by parasite">Infestations</span>:</span>
</li>
<li><span class="product-label-link" type="condition" conceptid="4217621" conceptname="Black hairy tongue">Black hairy tongue</span>, and hemorrhagic/<span class="product-label-link" type="condition" conceptid="4265457" conceptname="Pseudomembranous enterocolitis">pseudomembranous colitis</span>. Onset of <span class="product-label-link" type="condition" conceptid="4265457" conceptname="Pseudomembranous enterocolitis">pseudomembranous colitis</span> symptoms may occur during or after antibacterial treatment .
                                        <span class="Bold">Gastrointestinal:</span><span class="Italics">[see ]
                                            <a href="#Section_5.2">Warnings and Precautions (5.2)</a></span>
</li>
<li><span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">Anaphylaxis</span> . Serum sicknessâ€“like reactions, erythematous <span class="product-label-link" type="condition" conceptid="4083795" conceptname="Maculopapular eruption">maculopapular rashes</span>, <span class="product-label-link" type="condition" conceptid="132702" conceptname="Erythema multiforme">erythema multiforme</span>, <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson syndrome</span>, <span class="product-label-link" type="condition" conceptid="4270887" conceptname="Erythroderma">exfoliative dermatitis</span>, <span class="product-label-link" type="condition" conceptid="443754" conceptname="Lyell's toxic epidermal necrolysis, subepidermal type">toxic epidermal necrolysis</span>, <span class="product-label-link" type="condition" conceptid="45773387" conceptname="Acute generalized exanthematous pustulosis">acute generalized exanthematous pustulosis</span>, <span class="product-label-link" type="condition" conceptid="196431" conceptname="Hypersensitivity angiitis">hypersensitivity vasculitis</span>, and <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span> have been reported.
                                        <span class="Bold"><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity Reactions</span>:</span><span class="Italics">[see ]
                                            <a href="#Section_5.1">Warnings and Precautions (5.1)</a></span>
</li>
<li>A moderate rise in AST and/or ALT has been noted, but the significance of this finding is unknown. Hepatic dysfunction including <span class="product-label-link" type="condition" conceptid="4185719" conceptname="Cholestatic jaundice syndrome">cholestatic jaundice</span>, hepatic <span class="product-label-link" type="condition" conceptid="4143915" conceptname="Cholestasis">cholestasis</span> and <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">acute cytolytic hepatitis</span> have been reported.
                                        <span class="Bold">Liver:</span>
</li>
<li><span class="product-label-link" type="condition" conceptid="4188213" conceptname="Crystalluria">Crystalluria</span> has been reported .
                                        <span class="Bold">Renal:</span><span class="Italics">[see ]
                                            <a href="#Section_10">Overdosage (10)</a></span>
</li>
<li><span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">Anemia</span>, including <span class="product-label-link" type="condition" conceptid="435503" conceptname="Hemolytic anemia">hemolytic anemia</span>, <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>, <span class="product-label-link" type="condition" conceptid="4119134" conceptname="Thrombocytopenic purpura">thrombocytopenic purpura</span>, <span class="product-label-link" type="condition" conceptid="4302954" conceptname="Disorder characterized by eosinophilia">eosinophilia</span>, <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span>, and <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">agranulocytosis</span> have been reported. These reactions are usually reversible on discontinuation of therapy and are believed to be <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> phenomena.
                                        <span class="Bold">Hemic and Lymphatic Systems:</span>
</li>
<li>Reversible <span class="product-label-link" type="condition" conceptid="4137162" conceptname="Overactive">hyperactivity</span>, <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span>, <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span>, <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span>, behavioral changes, and/or <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span> have been reported.
                                        <span class="Bold">Central Nervous System:</span>
</li>
<li><span class="product-label-link" type="condition" conceptid="45757361" conceptname="Mottled teeth">Tooth discoloration</span> (brown, yellow, or gray staining) has been reported. Most reports occurred in pediatric patients. Discoloration was reduced or eliminated with brushing or dental cleaning in most cases.
                                        <span class="Bold">Miscellaneous:</span>
</li>
</ul>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="Section_7"></a><a name="section-7"></a><p></p>
<h1>7 DRUG INTERACTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_7.1"></a><a name="section-7.1"></a><p></p>
<h2>7.1 Probenecid</h2>
<br><p class="First">Probenecid decreases the renal tubular secretion of amoxicillin. Concurrent use of amoxicillin and probenecid may result in increased and prolonged blood levels of amoxicillin.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_7.2"></a><a name="section-7.2"></a><p></p>
<h2>7.2 Oral Anticoagulants</h2>
<br><p class="First">Abnormal prolongation of <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> time (increased international normalized ratio [INR]) has been reported in patients receiving amoxicillin and oral anticoagulants. Appropriate monitoring should be undertaken when anticoagulants are prescribed concurrently. Adjustments in the dose of oral anticoagulants may be necessary to maintain the desired level of anticoagulation.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_7.3"></a><a name="section-7.3"></a><p></p>
<h2>7.3 Allopurinol</h2>
<br><p class="First">The concurrent administration of allopurinol and amoxicillin increases the incidence of <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rashes</span> in patients receiving both drugs as compared to patients receiving amoxicillin alone. It is not known whether this potentiation of amoxicillin <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rashes</span> is due to allopurinol or the <span class="product-label-link" type="condition" conceptid="4147761" conceptname="Hyperuricemia">hyperuricemia</span> present in these patients.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_7.4"></a><a name="section-7.4"></a><p></p>
<h2>7.4 Oral Contraceptives</h2>
<br><p class="First">Amoxicillin may affect the gut flora, leading to lower estrogen reabsorption and reduced efficacy of combined oral estrogen/progesterone contraceptives.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_7.5"></a><a name="section-7.5"></a><p></p>
<h2>7.5 Other Antibacterials</h2>
<br><p class="First">Chloramphenicol, macrolides, sulfonamides, and tetracyclines may interfere with the bactericidal effects of penicillin. This has been demonstrated ; however, the clinical significance of this interaction is not well documented.
                                    <span class="Italics">in vitro</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_7.6"></a><a name="section-7.6"></a><p></p>
<h2>7.6 Drug/Laboratory Interactions</h2>
<br><p class="First">High urine concentrations of ampicillin may result in false-positive reactions when testing for the presence of glucose in urine using CLINITEST , Benedictâ€™s Solution, or Fehlingâ€™s Solution. Since this effect may also occur with amoxicillin, it is recommended that glucose tests based on enzymatic glucose oxidase reactions (such as CLINISTIX ) be used.Â  Following administration of ampicillin or amoxicillin to pregnant women, a transient decrease in plasma concentration of total conjugated estriol, estriol-glucuronide, conjugated estrone, and estradiol has been noted.
                                    <span class="Sup">Â®</span><span class="Sup">Â®</span><br><br></p>
</div>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="Section_8"></a><a name="section-8"></a><p></p>
<h1>8 USE IN SPECIFIC POPULATIONS</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="Section_8.1"></a><a name="section-8.1"></a><p></p>
<h2>8.1 Pregnancy</h2>
<br><p class="First">Â  Pregnancy Category B.Â Reproduction studies have been performed in mice and rats at doses up to 2000 mg/kg (3 and 6 times the 3 g human dose, based on body surface area). There was no evidence of harm to the fetus due to amoxicillin. There are, however, no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, amoxicillin should be used during pregnancy only if clearly needed.
                                    <span class="Underline">Teratogenic Effects:</span></p>
</div>
<div class="Section" data-sectionCode="34079-4">
<a name="Section_8.2"></a><a name="section-8.2"></a><p></p>
<h2>8.2 Labor and Delivery</h2>
<br><p class="First">Oral ampicillin is poorly absorbed during labor. It is not known whether use of amoxicillin in humans during labor or delivery has immediate or delayed adverse effects on the fetus, prolongs the duration of labor, or increases the likelihood of the necessity for an obstetrical intervention.</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="Section_8.3"></a><a name="section-8.3"></a><p></p>
<h2>8.3 Nursing Mothers</h2>
<br><p class="First">Penicillins have been shown to be excreted in human milk. Amoxicillin use by nursing mothers may lead to sensitization of infants. Caution should be exercised when amoxicillin is administered to a nursing woman.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="Section_8.4"></a><a name="section-8.4"></a><p></p>
<h2>8.4 Pediatric Use</h2>
<br><p class="First">Because of incompletely developed renal function in neonates and young infants, the elimination of amoxicillin may be delayed. Dosing of amoxicillin should be modified in pediatric patients 12 weeks or younger (â‰¤ 3 months).
                                    <span class="Italics">[See .]
                                        <a href="#Section_2.2">Dosage and Administration (2.2)</a></span></p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="Section_8.5"></a><a name="section-8.5"></a><p></p>
<h2>8.5 Geriatric Use</h2>
<br><p class="First">An analysis of clinical studies of amoxicillin was conducted to determine whether subjects aged 65 and over respond differently from younger subjects. These analyses have not identified differences in responses between the elderly and younger patients, but a greater sensitivity of some older individuals cannot be ruled out. This drug is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span>. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function.
                                    <br><br></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_8.6"></a><a name="section-8.6"></a><p></p>
<h2>8.6 Dosing in <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></h2>
<br><p class="First">Amoxicillin is primarily eliminated by the kidney and dosage adjustment is usually required in patients with severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (GFR &lt;30 mL/min). See for specific recommendations in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>.
                                    <span class="Italics">Â </span><a href="#Section_2.4">Dosing in <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span> (2.4)</a></p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="Section_10"></a><a name="section-9"></a><p></p>
<h1>10 OVERDOSAGE</h1>
<br><p class="First">In case of overdosage, discontinue medication, treat symptomatically, and institute supportive measures as required. A prospective study of 51 pediatric patients at a poison-control center suggested that overdosages of less than 250 mg/kg of amoxicillin are not associated with significant clinical symptoms. Interstitial <span class="product-label-link" type="condition" conceptid="193253" conceptname="Nephritis">nephritis</span> resulting in oliguric <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal failure</span> has been reported in a small number of patients after overdosage with amoxicillin . <span class="product-label-link" type="condition" conceptid="4188213" conceptname="Crystalluria">Crystalluria</span>, in some cases leading to <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal failure</span>, has also been reported after amoxicillin overdosage in adult and pediatric patients. In case of overdosage, adequate fluid intake and <span class="product-label-link" type="condition" conceptid="79936" conceptname="Polyuria">diuresis</span> should be maintained to reduce the risk of amoxicillin <span class="product-label-link" type="condition" conceptid="4188213" conceptname="Crystalluria">crystalluria</span>. <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal impairment</span> appears to be reversible with cessation of drug administration. High blood levels may occur more readily in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span> because of decreased renal clearance of amoxicillin. Amoxicillin may be removed from circulation by hemodialysis.
                            <span class="Sup">1</span><br><br><br><br></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="Section_11"></a><a name="section-10"></a><p></p>
<h1>11 DESCRIPTION</h1>
<br><p class="First">Formulation of amoxicillin capsules, USP contains amoxicillin, a semisynthetic antibiotic, an analog of ampicillin, with a broad spectrum of bactericidal activity against many Gram-positive and Gram-negative microorganisms. Chemically, it is (2 ,5 ,6 )-6-[( )-(-)-2-amino-2-( -hydroxyphenyl)acetamido]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid trihydrate. It may be represented structurally as:
                            <span class="Italics">S</span><span class="Italics">R</span><span class="Italics">R</span><span class="Italics">R</span><span class="Italics">p</span></p>
<br><div class="Figure"><img alt="Chemical Structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=c2f6b402-27cd-48d4-95ae-6a3f530b0452&amp;name=amoxicillin-str.jpg"></div>
<br><p>The amoxicillin molecular formula is C H N O Sâ€¢3H O, and the molecular weight is 419.45. Each capsule of amoxicillin with blue cap and pink body, contains 250 mg or 500 mg amoxicillin USP as the trihydrate. The body of the 250 mg capsule is imprinted with 'A44' in black ink. The body of the 500 mg capsule is imprinted with 'A45' in black ink. Inactive ingredients: D&amp;C Red No. 28, FD&amp;C Blue No. 1, FD&amp;C Red No. 40, gelatin, magnesium stearate, microcrystalline cellulose, sodium lauryl sulfate, and titanium dioxide.Â  Meets USP Dissolution Test 2.
                            <span class="Sub">16</span><span class="Sub">19</span><span class="Sub">3</span><span class="Sub">5</span><span class="Sub">2</span><br><br><br><br></p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="Section_12"></a><a name="section-11"></a><p></p>
<h1>12 CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="Section_12.1"></a><a name="section-11.1"></a><p></p>
<h2>12.1 Mechanism of Action</h2>
<br><p class="First">Amoxicillin is an antibacterial drug
                                    <span class="Italics">[see ].
                                        <a href="#Section_12.4">Microbiology (12.4)</a></span></p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="Section_12.3"></a><a name="section-11.2"></a><p></p>
<h2>12.3 Pharmacokinetics</h2>
<br><p class="First">Amoxicillin is stable in the presence of gastric acid and is rapidly absorbed after oral administration. The effect of food on the absorption of amoxicillin from the tablets and suspension of amoxicillin has been partially investigated; 400 mg and 875 mg formulations have been studied only when administered at the start of a light meal. Orally administered doses of 250 mg and 500 mg amoxicillin capsules result in average peak blood levels 1 to 2 hours after administration in the range of 3.5 mcg/mL to 5 mcg/mL and 5.5 mcg/mL to 7.5 mcg/mL, respectively. Mean amoxicillin pharmacokinetic parameters from an open, two-part, single-dose crossover bioequivalence study in 27 adults comparing 875 mg of amoxicillin with 875 mg ofÂ amoxicillin and clavulanate potassium showed that the 875 mg tablet of amoxicillin produces an AUC of 35.4 Â± 8.1 mcgâ€¢hr/mL and a C of 13.8 Â± 4.1 mcg/mL. Dosing was at the start of a light meal following an overnight fast. Orally administered doses of amoxicillin suspension, 125 mg/5 mL and 250 mg/5 mL, result in average peak blood levels 1 to 2 hours after administration in the range of 1.5 mcg/mL to 3 mcg/mL and 3.5 mcg/mL to 5 mcg/mL, respectively. Oral administration of single doses of 400 mg chewable tablets and 400 mg/5 mL suspension of amoxicillin to 24 adult volunteers yielded comparable pharmacokinetic data:
                                    <span class="Underline">Absorption:</span><br><br><br><br><span class="Sub">0-âˆž</span><span class="Sub">max</span><br><br><br><br></p>
<br><br><table border="0" cellpadding="0" cellspacing="0" width="624">
<caption><span>Table 3. Mean Pharmacokinetic Parameters of Amoxicillin (400 mg chewable tablets and 400 mg/5 mL suspension) in Healthy Adults</span></caption>
<thead><tr class="First Last">
<th class="Lrule Rrule Toprule" align="center">Dose *</th>
<th class="Lrule Rrule Toprule" align="center">AUC (mcgâ€¢hr/mL)
                                                <span class="Sub">0-âˆž</span>
</th>
<th class="Lrule Rrule Toprule" align="center">Cmax (mcg/mL)
                                                <span class="Sup">â€ </span>
</th>
</tr></thead>
<tfoot><tr class="First Last"><td colspan="3">Administered at the start of a light meal. Mean values of 24 normal volunteers. Peak concentrations occurred approximately 1 hour after the dose.
                                                <span class="Sup">*</span><br><span class="Sup">â€ </span><br>
</td></tr></tfoot>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" valign="top">Â Amoxicillin
                                                <br>
</td>
<td class="Rrule" align="center" valign="top">Amoxicillin (Â±S.D.)
                                                <br>
</td>
<td class="Rrule" align="center" valign="top">Amoxicillin (Â±S.D.)
                                                <br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">Â 400 mg (5 mL of suspension)
                                                <br>
</td>
<td class="Rrule" align="center" valign="top">17.1 (3.1)
                                                <br>
</td>
<td class="Rrule" align="center" valign="top">5.92 (1.62)
                                                <br>
</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" valign="top">Â 400 mg (1 chewable tablet)
                                                <br>
</td>
<td class="Rrule" align="center" valign="top">17.9 (2.4)
                                                <br>
</td>
<td class="Rrule" align="center" valign="top">5.18 (1.64)
                                                <br>
</td>
</tr>
</tbody>
</table>
<br><p>Amoxicillin diffuses readily into most body tissues and fluids, with the exception of brain and spinal fluid, except when meninges are inflamed. In blood serum, amoxicillin is approximately 20% protein-bound. Following a 1 gram dose and utilizing a special skin window technique to determine levels of the antibiotic, it was noted that therapeutic levels were found in the interstitial fluid. The half-life of amoxicillin is 61.3 minutes. Approximately 60% of an orally administered dose of amoxicillin is excreted in the urine within 6 to 8 hours. Detectable serum levels are observed up to 8 hours after an orally administered dose of amoxicillin. Since most of the amoxicillin is excreted unchanged in the urine, its excretion can be delayed by concurrent administration of probenecid .
                                    <span class="Underline">Distribution:</span><br><br><span class="Underline">Metabolism and Excretion:</span><span class="Italics">[see ]
                                        <a href="#Section_7.1">Drug Interactions (7.1)</a></span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_12.4"></a><a name="section-11.3"></a><p></p>
<h2>12.4 Microbiology</h2>
<br><p class="First">Amoxicillin is similar to penicillin in its bactericidal action against susceptible bacteria during the stage of active multiplication. It acts through the inhibition of cell wall biosynthesis that leads to the <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> of the bacteria. Resistance to amoxicillin is mediated primarily through enzymes called beta-lactamases that cleave the beta-lactam ring of amoxicillin, rendering it inactive. Amoxicillin has been shown to be active against most isolates of the bacteria listed below, both and in clinical <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> as described in the section.
                                    <span class="Underline">Mechanism of Action</span><br><br><span class="Underline">Method of Resistance
                                        <br><br></span><br><br><br><br><span class="Italics">in vitro</span><span class="Bold"><a href="#Section_1">INDICATIONS AND USAGE</a></span></p>
<br><table border="0" cellpadding="0" cellspacing="0" width="402"><tbody class="Headless">
<tr class="Botrule First">
<td class="Lrule Rrule" valign="top">
<span class="Bold">Â Gram-Positive Bacteria</span><br>
</td>
<td class="Rrule" valign="top">
<span class="Bold">Â Gram-Negative Bacteria</span><br>
</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" valign="top">spp. Â Alpha and Î²-hemolytic streptococci.
                                                <span class="Italics">Â Enterococcus faecalis</span><br><span class="Italics">Â Staphylococcus</span><br><span class="Italics">Â Streptococcus pneumoniae</span><br><br>
</td>
<td class="Rrule" valign="top">
<span class="Italics">Â Escherichia coli</span><br><span class="Italics">Â Haemophilus influenzae</span><br><span class="Italics">Â Neisseria gonorrhoeae</span><br><span class="Italics">Â Proteus mirabilis</span><br><span class="Italics">Â Helicobacter pylori</span><br>
</td>
</tr>
</tbody></table>
<br><p>(susceptibility to amoxicillin can be determined using ampicillin powder and a 10 mcg ampicillin disk) When available, clinical microbiology should provide the results of susceptibility test results for antimicrobial drugs used in resident hospitals to the physician as periodic reports that describe the susceptibility profile of nosocomial and community-acquired pathogens. These reports should aid the physician in selecting an antimicrobial drug product for treatment. Quantitative methods are used to determine antimicrobial <span class="product-label-link" type="condition" conceptid="4190299" conceptname="Broth microdilution susceptibility test">minimum inhibitory concentrations</span> (MICs). These MICs provide estimates of the susceptibility of bacteria to antimicrobial compounds. The MICs should be determined using a standardized procedure. Standardized procedures are based on dilution methods (broth or agar) or equivalent with standardized inoculum concentrations and standardized concentrations of ampicillin powder. The MIC values should be interpreted according to the criteria in Table 4.
                                    <span class="Underline">Susceptibility Test Methods:</span><br><br><span class="Italics">in vitro</span><span class="Italics">Dilution Techniques:
                                        <br><br></span><span class="Sup">2,3</span><br><span class="Italics">Diffusion Techniques:
                                        <br></span></p>
<span class="Italics"></span><p>Quantitative methods that require measurement of zone diameters also provide reproducible estimates of the susceptibility of bacteria to antimicrobial compounds. One such standardized procedure requires the use of standardized inoculum concentrations. This procedure uses paper disks impregnated with 10 mcg ampicillin to test the susceptibility of bacteria to ampicillin. Interpretation involves correlation of the diameter obtained in the disk test with the MIC for amoxicillin. Reports from the laboratory providing results of the standard single-disk susceptibility test with a 10 mcg ampicillin disk should be interpreted according to the criteria listed in Table 4.
                                    <span class="Sup">3</span></p>
<br><table border="0" cellpadding="0" cellspacing="0" width="796">
<caption><span>Table 4. Susceptibility Test Interpretive Criteria for Amoxicillin</span></caption>
<thead>
<tr class="First">
<th class="Lrule Rrule Toprule" rowspan="2"></th>
<th class="Lrule Rrule Toprule" align="center" colspan="3"><span class="product-label-link" type="condition" conceptid="4190299" conceptname="Broth microdilution susceptibility test">Minimum Inhibitory Concentration</span> (mcg/mL)
                                                <br>
</th>
<th class="Lrule Rrule Toprule" align="center" colspan="3">Disk Diffusion (zone diameter in mm)
                                                <br>
</th>
</tr>
<tr class="Last">
<th class="Lrule Rrule Toprule" align="center">Susceptible</th>
<th class="Lrule Rrule Toprule" align="center">Intermediate</th>
<th class="Lrule Rrule Toprule" align="center">Resistant</th>
<th class="Lrule Rrule Toprule" align="center">Susceptible</th>
<th class="Lrule Rrule Toprule" align="center">Intermediate</th>
<th class="Lrule Rrule Toprule" align="center">Resistant</th>
</tr>
</thead>
<tfoot><tr class="First Last"><td colspan="7">* should be tested using a 1 mcg oxacillin disk. Isolates with oxacillin zone sizes of â‰¥ 20 mm are susceptible to amoxicillin. An amoxicillin MIC should be determined on isolates of with oxacillin zone sizes of â‰¤ 19 mm. **A positive beta lactamase test indicates resistance to amoxicillin. Isolates that are resistant to penicillin by MIC testing are also expected to be resistant to amoxicillin.
                                                <span class="Italics">S. pneumoniae</span><span class="Italics">S. pneumoniae</span><br><br>
</td></tr></tfoot>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" valign="top">spp.
                                                <span class="Italics">Â Enterococcus</span><br>
</td>
<td class="Rrule" align="center" valign="top">â‰¤ 8
                                                <br>
</td>
<td class="Rrule" align="center" valign="top">-
                                                <br>
</td>
<td class="Rrule" align="center" valign="top">â‰¥ 16
                                                <br>
</td>
<td class="Rrule" align="center" valign="top">â‰¥ 17
                                                <br>
</td>
<td class="Rrule" align="center" valign="top">-
                                                <br>
</td>
<td class="Rrule" align="center" valign="top">â‰¤ 16
                                                <br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">spp.
                                                <span class="Italics">Â Staphylococcus</span><br>
</td>
<td class="Rrule" align="center" valign="top">â‰¤ 0.25
                                                <br>
</td>
<td class="Rrule" align="center" valign="top">Â 
                                                <br>
</td>
<td class="Rrule" align="center" valign="top">â‰¥ 0.5
                                                <br>
</td>
<td class="Rrule" align="center" valign="top">â‰¥ 29
                                                <br>
</td>
<td class="Rrule" align="center" valign="top">Â 
                                                <br>
</td>
<td class="Rrule" align="center" valign="top">â‰¤ 28
                                                <br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">Â Streptococci, viridians group Â (alpha-hemolytic streptococci)
                                                <br><br>
</td>
<td class="Rrule" align="center" valign="top">â‰¤ 0.25
                                                <br>
</td>
<td class="Rrule" align="center" valign="top">0.5 to 4
                                                <br>
</td>
<td class="Rrule" align="center" valign="top">â‰¥ 8
                                                <br>
</td>
<td class="Rrule" align="center" valign="top">-
                                                <br>
</td>
<td class="Rrule" align="center" valign="top">-
                                                <br>
</td>
<td class="Rrule" align="center" valign="top">-
                                                <br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">Â Î²-hemolytic streptococci
                                                <br>
</td>
<td class="Rrule" align="center" valign="top">â‰¤ 0.25
                                                <br>
</td>
<td class="Rrule" align="center" valign="top">-
                                                <br>
</td>
<td class="Rrule" align="center" valign="top">-
                                                <br>
</td>
<td class="Rrule" align="center" valign="top">â‰¥ 24
                                                <br>
</td>
<td class="Rrule" align="center" valign="top">-
                                                <br>
</td>
<td class="Rrule" align="center" valign="top">-
                                                <br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">Â (non-<span class="product-label-link" type="condition" conceptid="435785" conceptname="Meningitis">meningitis</span> isolates)*
                                                <span class="Italics">Â Streptococcus pneumoniae</span><br><span class="Italics"></span><br>
</td>
<td class="Rrule" align="center" valign="top">â‰¤ 2
                                                <br>
</td>
<td class="Rrule" align="center" valign="top">4
                                                <br>
</td>
<td class="Rrule" align="center" valign="top">â‰¥ 8
                                                <br>
</td>
<td class="Rrule" align="center" valign="top">-
                                                <br>
</td>
<td class="Rrule" align="center" valign="top">-
                                                <br>
</td>
<td class="Rrule" align="center" valign="top">-
                                                <br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">
<span class="Italics">Â Enterobacteriaceae</span><br>
</td>
<td class="Rrule" align="center" valign="top">â‰¤ 8
                                                <br>
</td>
<td class="Rrule" align="center" valign="top">16
                                                <br>
</td>
<td class="Rrule" align="center" valign="top">â‰¥ 32
                                                <br>
</td>
<td class="Rrule" align="center" valign="top">â‰¥ 17
                                                <br>
</td>
<td class="Rrule" align="center" valign="top">14 to 16
                                                <br>
</td>
<td class="Rrule" align="center" valign="top">â‰¤ 13
                                                <br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">
<span class="Italics">Â Haemophilus influenzae</span><br>
</td>
<td class="Rrule" align="center" valign="top">â‰¤ 1
                                                <br>
</td>
<td class="Rrule" align="center" valign="top">2
                                                <br>
</td>
<td class="Rrule" align="center" valign="top">â‰¥ 4
                                                <br>
</td>
<td class="Rrule" align="center" valign="top">â‰¥ 22
                                                <br>
</td>
<td class="Rrule" align="center" valign="top">19 to 21
                                                <br>
</td>
<td class="Rrule" align="center" valign="top">â‰¤ 18
                                                <br>
</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" valign="top">
<span class="Italics">Â Neisseria gonorrhoeae**</span><br>
</td>
<td class="Rrule" align="center" valign="top">-
                                                <br>
</td>
<td class="Rrule" align="center" valign="top">-
                                                <br>
</td>
<td class="Rrule" align="center" valign="top">-
                                                <br>
</td>
<td class="Rrule" align="center" valign="top">-
                                                <br>
</td>
<td class="Rrule" align="center" valign="top">-
                                                <br>
</td>
<td class="Rrule" align="center" valign="top">-
                                                <br>
</td>
</tr>
</tbody>
</table>
<br><p>A report of â€œSusceptibleâ€? indicates the pathogen is likely to be inhibited if the antimicrobial compound in the blood reaches concentrations that are usually achievable. A report of â€œIntermediateâ€? indicates that result should be considered equivocal, and, if the microorganism is not fully susceptible to alternative, clinically feasible drugs, the test should be repeated. The intermediate category implies possible clinical applicability in body sites where the drug is physiologically concentrated or in situations where high dosage of drug can be used. The intermediate category also provides a buffer zone, which prevents small uncontrolled technical factors from causing major discrepancies in interpretation. A report of â€œResistantâ€? indicates the pathogen is not likely to be inhibited if the antimicrobial compound in the blood reaches concentrations that are usually achievable and other therapy(ies) are likely to be preferred. Susceptibility techniques require use of laboratory control microorganisms to control the technical aspects of the laboratory standardized procedures. Standard ampicillin powder should provide the MIC values described below. For the diffusion technique using the 10 mcg ampicillin disk, the criteria are provided in Table 5.
                                    <br><span class="Bold">Â 
                                        <span class="Italics">Quality Control
                                            <br></span><br><br></span><span class="Sup">2,3,4</span></p>
<br><br><table border="0" cellpadding="0" cellspacing="0" width="610">
<caption><span>Table 5. Acceptable Quality Control Ranges for Amoxicillin</span></caption>
<thead><tr class="First Last">
<th class="Lrule Rrule Toprule" align="center">Bacteria</th>
<th class="Lrule Rrule Toprule" align="center">ATCC#</th>
<th class="Lrule Rrule Toprule" align="center">MIC Range (mcg/mL)
                                                <br>
</th>
<th class="Lrule Rrule Toprule" align="center">Disk Diffusion Zone Range (mm)
                                                <br>
</th>
</tr></thead>
<tfoot><tr class="First Last"><td colspan="4">ATCC = American Type Culture Collection
                                                <span class="Sup">#</span><br>
</td></tr></tfoot>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" valign="top">
<span class="Italics">Escherichia coli</span><br>
</td>
<td class="Rrule" align="center" valign="top">25922
                                                <br>
</td>
<td class="Rrule" align="center" valign="top">2 to 8
                                                <br>
</td>
<td class="Rrule" align="center" valign="top">16 to 22
                                                <br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">
<span class="Italics">Enterococcus faecalis</span><br>
</td>
<td class="Rrule" align="center" valign="top">29212
                                                <br>
</td>
<td class="Rrule" align="center" valign="top">0.5 to 2
                                                <br>
</td>
<td class="Rrule" align="center" valign="top">Â 
                                                <br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">
<span class="Italics">Haemophilus influenzae</span><br>
</td>
<td class="Rrule" align="center" valign="top">49247
                                                <br>
</td>
<td class="Rrule" align="center" valign="top">2 to 8
                                                <br>
</td>
<td class="Rrule" align="center" valign="top">13 to 21
                                                <br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" rowspan="2" valign="top">
<span class="Italics">Staphylococcus aureus</span><br>
</td>
<td class="Rrule" align="center" valign="top">29213
                                                <br>
</td>
<td class="Rrule" align="center" valign="top">0.5 to 2
                                                <br>
</td>
<td class="Rrule" align="center" valign="top">Â 
                                                <br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center" valign="top">25923
                                                <br>
</td>
<td class="Rrule" align="center" valign="top">Â 
                                                <br>
</td>
<td class="Rrule" align="center" valign="top">27 to 35
                                                <br>
</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" valign="top">
<span class="Italics">Streptococcus pneumoniae</span><br>
</td>
<td class="Rrule" align="center" valign="top">49619
                                                <br>
</td>
<td class="Rrule" align="center" valign="top">0.06 to 0.25
                                                <br>
</td>
<td class="Rrule" align="center" valign="top">Â 
                                                <br>
</td>
</tr>
</tbody>
</table>
<p>Amoxicillin susceptibility testing methods for determining <span class="product-label-link" type="condition" conceptid="4190299" conceptname="Broth microdilution susceptibility test">minimum inhibitory concentrations</span> (MICs) and zone sizes have not been standardized, validated, or approved for testing . Specimens for and clarithromycin susceptibility test results should be obtained on isolates from patients who fail triple therapy. If clarithromycin resistance is found, a non-clarithromycin-containing regimen should be used.
                                    <span class="Underline">Susceptibility Testing for :
                                        <span class="Italics">Helicobacter pylori</span></span><span class="Italics">in vitro</span><span class="Italics">H. pylori</span><span class="Italics">H. pylori</span></p>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="Section_13"></a><a name="section-12"></a><p></p>
<h1>13 NONCLINICAL TOXICOLOGY</h1>
<div class="Section" data-sectionCode="34083-6">
<a name="Section_13.1"></a><a name="section-12.1"></a><p></p>
<h2>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<br><p class="First">Long-term studies in animals have not been performed to evaluate carcinogenic potential. Studies to detect mutagenic potential of amoxicillin alone have not been conducted; however, the following information is available from tests on a 4:1 mixture of amoxicillin and potassium clavulanate. Amoxicillin and potassium clavulanate was non-mutagenic in the Ames bacterial mutation assay, and the yeast gene conversion assay. Amoxicillin and potassium clavulanate was weakly positive in the mouse <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span> assay, but the trend toward increased mutation frequencies in this assay occurred at doses that were also associated with decreased cell survival. Amoxicillin and potassium clavulanate was negative in the mouse micronucleus test and in the dominant lethal assay in mice. Potassium clavulanate alone was tested in the Ames bacterial mutation assay and in the mouse micronucleus test, and was negative in each of these assays. In a multi-generation reproduction study in rats, no impairment of fertility or other adverse reproductive effects were seen at doses up to 500 mg/kg (approximately 2 times the 3 g human dose based on body surface area).</p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="Section_14"></a><a name="section-13"></a><p></p>
<h1>14 CLINICAL STUDIES</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_14.1"></a><a name="section-13.1"></a><p></p>
<h2>14.1 H. pylori Eradication to Reduce the Risk of <span class="product-label-link" type="condition" conceptid="4057053" conceptname="Acute duodenal ulcer">Duodenal Ulcer</span> Recurrence</h2>
<br><p class="First">Randomized, double-blind clinical studies performed in the United States in patients with and <span class="product-label-link" type="condition" conceptid="4057053" conceptname="Acute duodenal ulcer">duodenal ulcer</span> disease (defined as an active <span class="product-label-link" type="condition" conceptid="4177703" conceptname="Ulcer">ulcer</span> or history of an <span class="product-label-link" type="condition" conceptid="4177703" conceptname="Ulcer">ulcer</span> within 1 year) evaluated the efficacy of lansoprazole in combination with amoxicillin capsules and clarithromycin tablets as triple 14-day therapy, or in combination with amoxicillin capsules as dual 14-day therapy, for the eradication of . Based on the results of these studies, the safety and efficacy of 2 different eradication regimens were established: Amoxicillin 1 gram twice daily/clarithromycin 500 mg twice daily/lansoprazole 30 mg twice daily (see Table 6). Amoxicillin 1 gram three times daily/lansoprazole 30 mg three times daily (see Table 7). All treatments were for 14 days. eradication was defined as 2 negative tests (culture and histology) at 4 to 6 weeks following the end of treatment. Triple therapy was shown to be more effective than all possible dual therapy combinations. Dual therapy was shown to be more effective than both monotherapies. Eradication of has been shown to reduce the risk of <span class="product-label-link" type="condition" conceptid="4057053" conceptname="Acute duodenal ulcer">duodenal ulcer</span> recurrence.
                                    <span class="Italics">H. pylori</span><span class="Italics">H. pylori</span><span class="Bold">Triple Therapy:
                                        <br><br></span><br><span class="Bold">Dual Therapy:
                                        <br></span><span class="Italics">H. pylori</span><span class="Italics">H. pylori</span></p>
<br><table border="0" cellpadding="0" cellspacing="0" width="426">
<caption><span>Table 6. H. pylori Eradication Rates When Amoxicillin is Administered as Part of a Triple Therapy Regimen</span></caption>
<thead>
<tr class="First">
<th class="Lrule Rrule Toprule" rowspan="2">Study</th>
<th class="Lrule Rrule Toprule" align="center">Triple Therapy</th>
<th class="Lrule Rrule Toprule" align="center">Triple Therapy</th>
</tr>
<tr class="Last">
<th class="Lrule Rrule Toprule" align="center">Evaluable Analysis [95% Confidence Interval] (number of patients)
                                                <span class="Sup">a</span><br><br>
</th>
<th class="Lrule Rrule Toprule" align="center">Intent-to-Treat Analysis [95% Confidence Interval] (number of patients)
                                                <span class="Sup">b</span><br><br>
</th>
</tr>
</thead>
<tfoot><tr class="First Last"><td colspan="3">This analysis was based on evaluable patients with confirmed <span class="product-label-link" type="condition" conceptid="4057053" conceptname="Acute duodenal ulcer">duodenal ulcer</span> (active or within 1 year) and <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> at baseline defined as at least 2 of 3 positive endoscopic tests from CLOtest , histology, and/or culture. Patients were included in the analysis if they completed the study. Additionally, if patients dropped out of the study due to an adverse event related to the study drug, they were included in the analysis as failures of therapy. Patients were included in the analysis if they had documented <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> at baseline as defined above and had a confirmed <span class="product-label-link" type="condition" conceptid="4057053" conceptname="Acute duodenal ulcer">duodenal ulcer</span> (active or within 1 year). All dropouts were included as failures of therapy.
                                                <span class="Sup">a</span><span class="Italics">H. pylori</span><span class="Sup">Â®</span><br><span class="Sup">b</span><span class="Italics">H. pylori</span><br>
</td></tr></tfoot>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" valign="top">Â Study 1
                                                <br>
</td>
<td class="Rrule" align="center" valign="top">92 [80 - 97.7] (n = 48)
                                                <br><br><br>
</td>
<td class="Rrule" align="center" valign="top">86 [73.3 - 93.5] (n = 55)
                                                <br><br><br>
</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" valign="top">Â Study 2
                                                <br>
</td>
<td class="Rrule" align="center" valign="top">86 [75.7 - 93.6] (n = 66)
                                                <br><br><br>
</td>
<td class="Rrule" align="center" valign="top">83 [72 - 90.8] (n = 70)
                                                <br><br><br>
</td>
</tr>
</tbody>
</table>
<table border="0" cellpadding="0" cellspacing="0" width="432">
<caption><span>Table 7. H. pylori Eradication Rates When Amoxicillin is Administered as Part of a Dual Therapy Regimen</span></caption>
<thead>
<tr class="First">
<th class="Lrule Rrule Toprule" align="center" rowspan="2">Study</th>
<th class="Lrule Rrule Toprule" align="center">Dual Therapy</th>
<th class="Lrule Rrule Toprule" align="center">Dual Therapy</th>
</tr>
<tr class="Last">
<th class="Lrule Rrule Toprule" align="center">Evaluable Analysis [95% Confidence Interval] (number of patients)
                                                <span class="Sup">a</span><br><br>
</th>
<th class="Lrule Rrule Toprule" align="center">Intent-to-Treat Analysis [95% Confidence Interval] (number of patients)
                                                <span class="Sup">b</span><br><br>
</th>
</tr>
</thead>
<tfoot><tr class="First Last"><td colspan="3">This analysis was based on evaluable patients with confirmed <span class="product-label-link" type="condition" conceptid="4057053" conceptname="Acute duodenal ulcer">duodenal ulcer</span> (active or within 1 year) and <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> at baseline defined as at least 2 of 3 positive endoscopic tests from CLOtest , histology, and/or culture. Patients were included in the analysis if they completed the study. Additionally, if patients dropped out of the study due to an adverse event related to the study drug, they were included in the analysis as failures of therapy. Patients were included in the analysis if they had documented <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> at baseline as defined above and had a confirmed <span class="product-label-link" type="condition" conceptid="4057053" conceptname="Acute duodenal ulcer">duodenal ulcer</span> (active or within 1 year). All dropouts were included as failures of therapy.
                                                <span class="Sup">a</span><span class="Italics">H. pylori</span><span class="Sup">Â®</span><br><span class="Sup">b</span><span class="Italics">H. pylori</span><br>
</td></tr></tfoot>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" align="center" valign="top">Study 1
                                                <br>
</td>
<td class="Rrule" align="center" valign="top">77 [62.5 - 87.2] (n = 51)
                                                <br><br><br>
</td>
<td class="Rrule" align="center" valign="top">70 [56.8 - 81.2] (n = 60)
                                                <br><br><br>
</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="center" valign="top">Study 2
                                                <br>
</td>
<td class="Rrule" align="center" valign="top">66 [51.9 - 77.5] (n = 58)
                                                <br><br><br>
</td>
<td class="Rrule" align="center" valign="top">61 [48.5 - 72.9] (n = 67)
                                                <br><br><br>
</td>
</tr>
</tbody>
</table>
</div>
</div>
<div class="Section" data-sectionCode="34093-5">
<a name="Section_15"></a><a name="section-14"></a><p></p>
<h1>15 REFERENCES</h1>
<ol class="Arabic">
<li>Swanson-Biearman B, Dean BS, Lopez G, Krenzelok EP. The effects of penicillin and cephalosporin ingestions in children less than six years of age. Vet Hum Toxicol. 1988; 30: 66-67.</li>
<li>Clinical and Laboratory Standards Institute (CLSI). Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically; Approved Standard â€“ 8 ed. CLSI Document M7-A8, Vol. 29, No.2. CLSI, Wayne, PA, Jan. 2009.
                                <span class="Sup">th</span>
</li>
<li>Clinical and Laboratory Standards Institute (CLSI). Performance Standard for Antimicrobial Disk Susceptibility Tests; Approved Standard â€“ 10 ed. CLSI Document M2-A10, Vol. 29, No. 1. CLSI, Wayne, PA, 2009.
                                <span class="Sup">th</span>
</li>
<li>Clinical and Laboratory Standards Institute (CLSI). Performance Standards for Antimicrobial Susceptibility Testing: 21 Informational Supplement. Approved Standard CLSI Document M100-S21 CLSI, Wayne, PA, January 2011.
                                <span class="Sup">st</span>
</li>
</ol>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="Section_16"></a><a name="section-15"></a><p></p>
<h1>16 HOW SUPPLIED/STORAGE AND HANDLING</h1>
<p class="First">NDC:64725-0017-1 in a BOTTLE of 100 CAPSULES</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="Section_17"></a><a name="section-16"></a><p></p>
<h1>17 PATIENT COUNSELING INFORMATION</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_17.1"></a><a name="section-16.1"></a><p></p>
<h2>17.1 Information for Patients</h2>
<ul class="Disc">
<li>Patients should be advised that amoxicillin may be taken every 8 hours or every 12 hours, depending on the dose prescribed.</li>
<li>Patients should be counseled that antibacterial drugs, including amoxicillin, should only be used to treat <span class="product-label-link" type="condition" conceptid="432545" conceptname="Bacterial infectious disease">bacterial infections</span>. They do not treat <span class="product-label-link" type="condition" conceptid="440029" conceptname="Viral disease">viral infections</span> (e.g., the <span class="product-label-link" type="condition" conceptid="260427" conceptname="Common cold">common cold</span>). When amoxicillin is prescribed to treat a <span class="product-label-link" type="condition" conceptid="432545" conceptname="Bacterial infectious disease">bacterial infection</span>, patients should be told that although it is common to feel better early in the course of therapy, the medication should be taken exactly as directed. Skipping doses or not completing the full course of therapy may: (1) decrease the effectiveness of the immediate treatment, and (2) increase the likelihood that bacteria will develop resistance and will not be treatable by amoxicillin or other antibacterial drugs in the future.</li>
<li>Patients should be counseled that <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> is a common problem caused by antibiotics, and it usually ends when the antibiotic is discontinued. Sometimes after starting treatment with antibiotics, patients can develop watery and <span class="product-label-link" type="condition" conceptid="443530" conceptname="Hematochezia">bloody stools</span> (with or without <span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">stomach cramps</span> and <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>) even as late as 2 or more months after having taken their last dose of the antibiotic. If this occurs, patients should contact their physician as soon as possible.</li>
<li>Patients should be aware that amoxicillin contains a penicillin class drug product that can cause <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span> in some individuals.</li>
</ul>
<br><p class="First">CLINITEST is a registered trademark of Siemens Medical Solutions Diagnostics, and Ames Company, Inc. CLINISTIX is a registered trademark of Bayer Healthcare Llc, and Ames Company, Inc. CLOtest is a registered trademark of Â Kimberly-Clark Worldwide, Inc.
                                    <span class="Sup">Â®</span><br><span class="Sup">Â®</span><br><span class="Sup">Â®</span></p>
</div>
</div>
<div class="Section" data-sectionCode="42230-3">
<a name="Unclassified_Section_28"></a><a name="section-17"></a><p></p>
<br><p class="First">Manufactured for: 2400 Route 130 North Dayton, NJ 08810 Manufactured by: Hyderabad-500 072, India Revised: 01/2014
                            <br><span class="Bold">Aurobindo Pharma USA, Inc.</span><br><br><br><br><br><span class="Bold">Aurobindo Pharma Limited</span><br><br><br></p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-18"></a><p></p>
<h1></h1>
<div class="Figure"><img alt="Label Image" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=c2f6b402-27cd-48d4-95ae-6a3f530b0452&amp;name=64725-0017.jpg"></div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>AMOXICILLIN
                                    Â 		
					</strong><br><span class="contentTableReg">amoxicillin capsule</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:64725-0017(NDC:65862-017)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>AMOXICILLIN</strong> (AMOXICILLIN ANHYDROUS) </td>
<td class="formItem">AMOXICILLIN ANHYDROUS</td>
<td class="formItem">500Â mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>D&amp;C RED NO. 28</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FD&amp;C BLUE NO. 1</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FD&amp;C RED NO. 40</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>GELATIN</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SODIUM LAURYL SULFATE</strong></td>
<td class="formItem">Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">BLUE,Â PINK</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">CAPSULE</td>
<td class="formLabel">Size</td>
<td class="formItem">23mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">A45</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">Â Â Â Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:64725-0017-1</td>
<td class="formItem">100  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA065271</td>
<td class="formItem">11/09/2005</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler -Â </span>TYA Pharmaceuticals
							(938389038)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Registrant -Â </span>TYA Pharmaceuticals (938389038)</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">TYA Pharmaceuticals</td>
<td class="formItem"></td>
<td class="formItem">938389038</td>
<td class="formItem">RELABEL(64725-0017), REPACK(64725-0017)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 1/2014<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>1ff9ff68-ac5f-4b77-b62a-7ca1b0919176</div>
<div>Set id: c2f6b402-27cd-48d4-95ae-6a3f530b0452</div>
<div>Version: 2</div>
<div>Effective Time: 20140130</div>
</div>
</div>Â <div class="DistributorName">TYA Pharmaceuticals</div></p>
</body></html>
